| scholarly article | Q13442814 |
| P2093 | author name string | Michael Ladomery | |
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| A missense mutation in the APC tumor suppressor gene disrupts an ASF/SF2 splicing enhancer motif and causes pathogenic skipping of exon 14. | Q45158736 | ||
| Downregulation of serine/arginine-rich splicing factor 3 induces G1 cell cycle arrest and apoptosis in colon cancer cells. | Q45732489 | ||
| The K-Ras 4A isoform promotes apoptosis but does not affect either lifespan or spontaneous tumor incidence in aging mice. | Q46791944 | ||
| Altered expression of heterogenous nuclear ribonucleoproteins and SR factors in human colon adenocarcinomas | Q77726451 | ||
| Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas | Q79856279 | ||
| K-ras 4A and 4B are co-expressed widely in human tissues, and their ratio is altered in sporadic colorectal cancer | Q80136633 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| p53 isoforms can regulate p53 transcriptional activity. | Q24319034 | ||
| Splice isoforms as therapeutic targets for colorectal cancer | Q27006500 | ||
| On the Origin of Cancer Cells | Q27861025 | ||
| Hypoxia in cancer: significance and impact on clinical outcome | Q28298305 | ||
| Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing | Q29547470 | ||
| Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. | Q34108288 | ||
| MicroRNA (miRNA)-mediated interaction between leukemia/lymphoma-related factor (LRF) and alternative splicing factor/splicing factor 2 (ASF/SF2) affects mouse embryonic fibroblast senescence and apoptosis | Q34141907 | ||
| Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma | Q34447216 | ||
| SC35 autoregulates its expression by promoting splicing events that destabilize its mRNAs | Q34583829 | ||
| Characterizing the Genetic Basis for Nicotine Induced Cancer Development: A Transcriptome Sequencing Study | Q34794845 | ||
| Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene | Q35095712 | ||
| The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation | Q35736854 | ||
| The gene encoding the splicing factor SF2/ASF is a proto-oncogene | Q36129226 | ||
| Unbalanced alternative splicing and its significance in cancer | Q36425627 | ||
| AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo | Q36532941 | ||
| p53 and its isoforms in cancer | Q36885363 | ||
| VEGF-A splicing: the key to anti-angiogenic therapeutics? | Q37035757 | ||
| p53 isoforms - a conspiracy to kidnap p53 tumor suppressor activity? | Q37293856 | ||
| Alternative pre-mRNA splicing in digestive tract malignancy | Q37816501 | ||
| Nuclear factor-κB, p53, and mitochondria: regulation of cellular metabolism and the Warburg effect | Q38012877 | ||
| Regulatory networks defining EMT during cancer initiation and progression | Q38076317 | ||
| Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression | Q38354644 | ||
| Skipping of an alternative intron in the srsf1 3' untranslated region increases transcript stability | Q39259256 | ||
| Downregulation of splicing factor SRSF3 induces p53β, an alternatively spliced isoform of p53 that promotes cellular senescence | Q39317407 | ||
| Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC. | Q39356444 | ||
| WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing | Q39427761 | ||
| SF2/ASF autoregulation involves multiple layers of post-transcriptional and translational control | Q39742308 | ||
| Alternative splicing and nonsense-mediated mRNA decay in the regulation of a new adenomatous polyposis coli transcript. | Q40159212 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | alternative mRNA splicing, via spliceosome | Q21114084 |
| P304 | page(s) | 463786 | |
| P577 | publication date | 2013-09-11 | |
| P1433 | published in | International Journal of Cell Biology | Q26842205 |
| P1476 | title | Aberrant alternative splicing is another hallmark of cancer | |
| P478 | volume | 2013 |
| Q64260811 | A Single-Subject Method to Detect Pathways Enriched With Alternatively Spliced Genes |
| Q89943697 | A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2 |
| Q36344038 | A principle of organization which facilitates broad Lamarckian-like adaptations by improvisation |
| Q36582277 | A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology |
| Q34044691 | Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes |
| Q91838906 | Aberrant alternative splicing in breast cancer |
| Q58603892 | Aberrant expression of alternative isoforms of transcription factors in hepatocellular carcinoma |
| Q64240589 | Aberrant mRNA splicing generates oncogenic RNA isoforms and contributes to the development and progression of cholangiocarcinoma |
| Q38931476 | Altered levels of miR-21, miR-125b-2*, miR-138, miR-155, miR-184, and miR-205 in oral squamous cell carcinoma and association with clinicopathological characteristics |
| Q50033988 | Alternative Splicing as a Target for Cancer Treatment. |
| Q47110708 | Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools. |
| Q37205238 | Alternative splicing of spleen tyrosine kinase differentially regulates colorectal cancer progression |
| Q36108838 | Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma |
| Q38735423 | Alternative splicing: the pledge, the turn, and the prestige : The key role of alternative splicing in human biological systems |
| Q57135534 | Androgen-dependent alternative mRNA isoform expression in prostate cancer cells |
| Q88735258 | Axed MUC4 (MUC4/X) aggravates pancreatic malignant phenotype by activating integrin-β1/FAK/ERK pathway |
| Q38305268 | BCLAF1 and its splicing regulator SRSF10 regulate the tumorigenic potential of colon cancer cells |
| Q89966184 | CHG: A Systematically Integrated Database of Cancer Hallmark Genes |
| Q26824298 | Connecting the speckles: Splicing kinases and their role in tumorigenesis and treatment response |
| Q50640562 | Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells. |
| Q38181233 | Exon identity crisis: disease-causing mutations that disrupt the splicing code |
| Q55649364 | Exploration of potential roles of a new LOXL2 splicing variant using network knowledge in esophageal squamous cell carcinoma. |
| Q36473639 | Functional divergence and convergence between the transcript network and gene network in lung adenocarcinoma |
| Q38849527 | Genome stability versus transcript diversity |
| Q98465791 | Genome-Wide Profiling of Alternative Splicing Signature Reveals Prognostic Predictor for Esophageal Carcinoma |
| Q98735814 | Genome-Wide Transcriptional Analysis Reveals Alternative Splicing Event Profiles in Hepatocellular Carcinoma and Their Prognostic Significance |
| Q89666762 | Genome-wide Analysis of the Alternative Splicing Profiles Revealed Novel Prognostic Index for Kidney Renal Cell Clear Cell Carcinoma |
| Q59138288 | Global Signaling Profiling in a Human Model of Tumorigenic Progression Indicates a Role for Alternative RNA Splicing in Cellular Reprogramming |
| Q38659439 | Identification of differentially expressed splice variants by the proteogenomic pipeline Splicify |
| Q36729581 | In-depth characterization of breast cancer tumor-promoting cell transcriptome by RNA sequencing and microarrays |
| Q93019982 | Integration of CLIP experiments of RNA-binding proteins: a novel approach to predict context-dependent splicing factors from transcriptomic data |
| Q28074931 | Microbial and Natural Metabolites That Inhibit Splicing: A Powerful Alternative for Cancer Treatment |
| Q38667428 | Mitochondria and the non-genetic origins of cell-to-cell variability: More is different. |
| Q42787889 | Modulation of alternative splicing contributes to cancer development: focusing on p53 isoforms, p53β and p53γ. |
| Q91790678 | Modulator-Dependent RBPs Changes Alternative Splicing Outcomes in Kidney Cancer |
| Q26747089 | Molecular signaling involving intrinsically disordered proteins in prostate cancer |
| Q91964895 | Multilayered control of exon acquisition permits the emergence of novel forms of regulatory control |
| Q38364283 | Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia |
| Q26753160 | Novel Molecular Markers for Breast Cancer |
| Q21129296 | Overexpression of Cancer-Associated Genes via Epigenetic Derepression Mechanisms in Gynecologic Cancer |
| Q92740947 | PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing |
| Q26799301 | Pre-mRNA Splicing in Plants: In Vivo Functions of RNA-Binding Proteins Implicated in the Splicing Process |
| Q58714868 | Profiles of alternative splicing in colorectal cancer and their clinical significance: A study based on large-scale sequencing data |
| Q39223617 | RNA splicing and splicing regulator changes in prostate cancer pathology |
| Q92025312 | Roles and mechanisms of alternative splicing in cancer - implications for care |
| Q49025200 | SQANTI: extensive characterization of long-read transcript sequences for quality control in full-length transcriptome identification and quantification. |
| Q60912033 | Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators |
| Q55257606 | Shift in VEGFA isoform balance towards more angiogenic variants is associated with tumor stage and differentiation of human hepatocellular carcinoma. |
| Q42216004 | Splice variants as novel targets in pancreatic ductal adenocarcinoma |
| Q92175081 | Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer |
| Q26798158 | Splicing Regulators and Their Roles in Cancer Biology and Therapy |
| Q57106833 | Splicing dysregulation as a driver of breast cancer |
| Q34507745 | Splicing mutation analysis reveals previously unrecognized pathways in lymph node-invasive breast cancer |
| Q90510554 | Systematic profiling of alternative splicing events and splicing factors in left- and right-sided colon cancer |
| Q37644995 | The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients |
| Q64080149 | TranscriptAchilles: a genome-wide platform to predict isoform biomarkers of gene essentiality in cancer |
| Q37680417 | Transcriptome analysis of alternative splicing events regulated by SRSF10 reveals position-dependent splicing modulation |
| Q99708877 | Transcriptomic Analysis Revealed an Emerging Role of Alternative Splicing in Embryonal Tumor with Multilayered Rosettes |
| Q34983690 | Unique expression features of cancer-type organic anion transporting polypeptide 1B3 mRNA expression in human colon and lung cancers |
| Q27000495 | Wrecked regulation of intrinsically disordered proteins in diseases: pathogenicity of deregulated regulators |
Search more.